Dynavax Technologies (NASDAQ:DVAX) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a buy rating to a strong-buy rating in a research report released on Saturday.

Several other equities analysts have also weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Price Performance

DVAX opened at $15.38 on Friday. The company has a fifty day moving average price of $11.10 and a two-hundred day moving average price of $10.58. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. Dynavax Technologies has a 52 week low of $9.20 and a 52 week high of $15.49. The firm has a market capitalization of $1.81 billion, a PE ratio of -41.57 and a beta of 0.89.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%.The company had revenue of $94.88 million for the quarter, compared to the consensus estimate of $94.00 million. As a group, analysts anticipate that Dynavax Technologies will post 0.32 earnings per share for the current year.

Institutional Investors Weigh In On Dynavax Technologies

Several institutional investors have recently added to or reduced their stakes in the stock. Capital Fund Management S.A. acquired a new stake in shares of Dynavax Technologies in the 2nd quarter valued at approximately $1,669,000. Jacobs Levy Equity Management Inc. acquired a new stake in Dynavax Technologies in the first quarter valued at $2,477,000. Hudson Bay Capital Management LP lifted its stake in Dynavax Technologies by 46.4% in the second quarter. Hudson Bay Capital Management LP now owns 541,600 shares of the biopharmaceutical company’s stock valued at $5,373,000 after acquiring an additional 171,700 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Dynavax Technologies by 222.3% in the 2nd quarter. Squarepoint Ops LLC now owns 435,577 shares of the biopharmaceutical company’s stock valued at $4,321,000 after acquiring an additional 300,421 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Dynavax Technologies by 28.7% during the 2nd quarter. American Century Companies Inc. now owns 375,716 shares of the biopharmaceutical company’s stock worth $3,727,000 after purchasing an additional 83,833 shares during the last quarter. 96.96% of the stock is owned by institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.